`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`10K 1 form10k.htm FORM 10K
`
`UNITED STATES
`SECURITIES AND EXCHANGE COMMISSION
`Washington, D.C. 20549
`FORM 10K
`
`[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
`
`For the fiscal year ended December 31, 2015
`
`[ ]
`
`TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
`1934
`
`For the transition period from __________to __________
`
`Commission File Number: 00031187
`IntelGenx Technologies Corp.
`(Exact name of registrant as specified in its charter)
`
`Delaware
`(State or other jurisdiction of incorporation or organization)
`
`870638336
`(I.R.S. Employer Identification No.)
`
`6420 Abrams, Ville SaintLaurent, Quebec
` (Address of principal executive offices)
`
`H4S 1Y2
`(Zip Code)
`
`(514) 3317440
`(Registrant’s telephone number, including area code)
`
`Securities registered pursuant to Section 12(b) of the Act:
`None
`
`Securities registered pursuant to Section 12(g) of the Act:
`Common Stock, $0.00001 par value per share
`
`Indicate by check mark if the registrant is a wellknown seasoned issuer, as defined in Rule 405 of the Securities Act.
`Yes [ ] No [X]
`
`Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
`Yes [ ] No [X]
`
`Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
`Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
`file such reports), and (2) has been subject to such filing requirements for the past 90 days.
`Yes [X] No [ ]
`
`Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any,
`every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation ST during the preceding
`12 months (or for such shorter period that the registrant was required to submit and post such files).
`Yes [X] No [ ]
`
`Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation SK is not contained herein,
`and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by
`reference in Part III of this Form 10K or any amendment to this Form 10K. [X]
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`1/93
`
`ICOS Exhibit 2004
`IntelGenX v. ICOS
`IPR2016-00678
`
`Page 1 of 93
`
`
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`30/03/2016
`Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonaccelerated filer, or a
`smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company”
`in Rule 12b2 of the Exchange Act. (Check one):
`
`Large accelerated filer [ ]
`
`
`Accelerated filer [ ]
`
`
`Nonaccelerated filer [ ]
`Smaller reporting company [X]
`(Do not check if a smaller reporting company)
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`2/93
`
`Page 2 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b2 of the Act).
`Yes [ ] No [X]
`
`As of June 30, 2015, the aggregate market value of the registrant’s voting and nonvoting common equity held by non
`affiliates of the registrant was $35,540,543 based on the closing price of the registrant’s common shares of U.S. $0.56, as
`reported on the OTCQX on that date. Shares of the registrant’s common shares held by each officer and director and each
`person who owns 10% or more of the outstanding common shares of the registrant have been excluded in that such persons
`may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other
`purposes.
`
`Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable
`
`date.
`
` Class
`Common Stock, $.00001 par value
`
`Outstanding at March 25, 2016
`63,615,256 shares
`
`DOCUMENTS INCORPORATED BY REFERENCE:
`
`Portions of the Company’s Proxy Statement for its 2016 Annual Meeting of Shareholders (the “2016 Proxy Statement”) are
`incorporated by reference into Part III
`
`2
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`3/93
`
`Page 3 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`TABLE OF CONTENTS
`
`
`
`PART I
`Item 1.
`Item 1A
`Item 1B
`Item 2.
`Item 3.
`Item 4.
`
`PART II
`Item 5.
`
`
`
`
`Business.
`Risk Factors.
`Unresolved Staff Comments.
`Properties.
`Legal Proceedings.
`Mine Safety Disclosures.
`
`
`Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
`Securities.
`Selected Financial Data.
`Item 6
`Management’s Discussion and Analysis of Financial Condition and Results of Operations.
`Item 7.
`Quantitative and Qualitative Disclosures About Market Risk.
`Item 7A
`Financial Statements and Supplementary Data.
`Item 8.
`Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
`Item 9.
`Controls and Procedures.
`Item 9A.
`Other Information.
`Item 9B.
`
`
`PART III
`
`Item 10.
`Directors, Executive Officers, and Corporate Governance.
`Executive Compensation.
`Item 11.
`Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
`Item 12.
`Certain Relationships and Related Transactions, and Director Independence.
`Item 13.
`Principal Accounting Fees and Services.
`Item 14.
`
`
`PART IV
`Item 15.
`Exhibits.
`
`Financial Statements Schedules.
`
`Page
`
`
`4
`14
`21
`21
`21
`21
`
`
`22
`
`23
`23
`34
`34
`34
`34
`35
`
`
`35
`35
`35
`35
`35
`
`
`36
`F1F
`28
`
`Terminology and references
`
`In this Annual Report on Form 10K, the words “Company”, “IntelGenx”, “we”, “us”, and “our”, refer collectively to
`IntelGenx Technologies Corp. and IntelGenx Corp., our whollyowned Canadian subsidiary.
`
`In this Form 10K, unless otherwise specified, all monetary amounts are in United States dollars, all references to “$”, “U.S.$”,
`“U.S. dollars” and “dollars” mean U.S. dollars and all references to “C$”, “Canadian dollars” and “CAD$” mean Canadian
`dollars. To the extent that such monetary amounts are derived from our consolidated financial statements included elsewhere in
`this Form 10K, they have been translated into U.S. dollars in accordance with our accounting policies as described therein.
`Unless otherwise indicated, other Canadian dollar monetary amounts have been translated into United States dollars at the
`December 31, 2015 closing rate reported by the Bank of Canada, being U.S. $1.00 = CAD$1.3841.
`
`3
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`4/93
`
`Page 4 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`PART I
`
`Cautionary Statement Concerning ForwardLooking Statements
`
`Certain statements included or incorporated by reference in this report constitute forwardlooking statements within the
`meaning of applicable securities laws. All statements contained in this report that are not clearly historical in nature are
`forwardlooking, and the words “anticipate”, “believe”, “continue”, “expect”, “estimate”, “intend”, “may”, “plan”, “will”,
`“shall” and other similar expressions are generally intended to identify forwardlooking statements within the meaning of
`Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All forwardlooking
`statements are based on our beliefs and assumptions based on information available at the time the assumption was made.
`These forwardlooking statements are not based on historical facts but on management’s expectations regarding future growth,
`results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding
`thereof), competitive advantages, business prospects and opportunities. Forwardlooking statements involve significant known
`and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, levels of activity,
`performance or achievements to differ materially from those implied by forwardlooking statements. These factors should be
`considered carefully and prospective investors should not place undue reliance on the forwardlooking statements. Although
`the forwardlooking statements contained in this report or incorporated by reference herein are based upon what management
`believes to be reasonable assumptions, there is no assurance that actual results will be consistent with these forwardlooking
`statements. These forwardlooking statements are made as of the date of this report or as of the date specified in the documents
`incorporated by reference herein, as the case may be. We undertake no obligation to update any forwardlooking statements
`to reflect events or circumstances after the date on which such statements were made or to reflect the occurrence of
`unanticipated events, except as may be required by applicable securities laws. The factors set forth in Item 1A., "Risk
`Factors", as well as any cautionary language in this report, provide examples of risks, uncertainties and events that may cause
`our actual results to differ materially from the expectations we describe in our forwardlooking statements. Before you invest in
`the common stock, you should be aware that the occurrence of the events described as risk factors and elsewhere in this report
`could have a material adverse effect on our business, operating results and financial condition.
`
`ITEM 1. BUSINESS.
`
`Corporate History
`
`Our predecessor company, Big Flash Corp., was incorporated in Delaware on July 27, 1999. On April 28, 2006, Big Flash,
`through its Canadian holding corporation, completed the acquisition of IntelGenx Corp., a Canadian company incorporated on
`June 15, 2003. The Company did not have any operations prior to the acquisition of IntelGenx Corp. In connection with the
`acquisition, we changed our name from Big Flash Corp. to IntelGenx Technologies Corp. IntelGenx Corp. has continued
`operations as our operating subsidiary.
`
`Overview
`
`We are a drug delivery company established in 2003 and headquartered in Montreal, Quebec, Canada. Our focus is on the
`development of novel oral immediaterelease and controlledrelease products for the pharmaceutical market. Our business
`strategy is to develop pharmaceutical products based on our proprietary drug delivery technologies and, once the viability of a
`product has been demonstrated, to license the commercial rights to partners in the pharmaceutical industry. In certain cases, we
`rely upon partners in the pharmaceutical industry to fund development of the licensed products, complete the regulatory
`approval process with the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies relating to the licensed
`products, and assume responsibility for marketing and distributing such products.
`
`In addition, we may choose to pursue the development of certain products until the project reaches the marketing and
`distribution stage. We will assess the potential for successful development of a product and associated costs, and then
`determine at which stage it is most prudent to seek a partner, balancing such costs against the potential for additional returns
`earned by partnering later in the development process.
`
`We have also undertaken a strategy under which we will work with pharmaceutical companies in order to develop new dosage
`forms for pharmaceutical products for which patent protection is nearing expiration. Under §(505)(b)(2) of the Food, Drug, and
`Cosmetics Act, the FDA may grant market exclusivity for a term of up to three years of exclusivity following approval of a
`listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of
`administration or combination. The 505(b)(2) pathway is also the regulatory approach to be followed if an applicant intends to
`file an application for a product containing a drug that is already approved by the FDA for a certain indication and for which
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`5/93
`
`Page 5 of 93
`
`
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`30/03/2016
`the applicant is seeking approval for a new indication or for a new use, the approval of which is required to be supported by
`new clinical trials, other than bioavailability studies. We have implemented a strategy under which we actively look for such
`socalled “repurposing opportunities” and determine whether our proprietary VersaFilm™ technology adds value to the
`product. We currently have two such drug repurposing projects in our development pipeline.
`
`4
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`6/93
`
`Page 6 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`We continue to develop the existing products in our pipeline and may also perform research and development on other
`potential products as opportunities arise.
`
`We are in the process of establishing a stateoftheart manufacturing facility for the future manufacture of our VersaFilm™
`products as we believe that this:
`
`
`
`
`
`
`1)
`2)
`
`3)
`
`represents a profitable business opportunity,
`will reduce our dependency upon thirdparty contract manufacturers, thereby protecting our manufacturing process
`know how and intellectual property, and
`allows us to offer our clients and development partners a full service from product conception through to supply of
`the finished product.
`
`Technology Platforms
`
`Our product development efforts are based upon three delivery platform technologies: (1) VersaFilm™, an Oral Film
`technology, (2) VersaTab™, a Multilayer Tablet technology, and (3) AdVersa™, a Mucoadhesive Tablet technology.
`
`VersaFilm™ is a drug delivery platform technology that enables the development of oral thin films, improving product
`performance:
`
`
`
`
`
`
`
`
`
`
`•
`•
`•
`•
`•
`
`•
`•
`
`Rapid disintegration without the need for water
`Quicker buccal or sublingual absorption
`Potential for faster onset of action and increased bioavailability
`Potential for reduced adverse effects by bypassing firstpass metabolism
`Easy administration for patients who have problems in swallowing: pediatric, geriatric, fear choking and/or
`suffering from nausea (e.g., nausea resulting from chemotherapy, radiotherapy or any surgical treatment)
`Pleasant taste
`Small and thin size, making it convenient for consumers
`
`The VersaFilm™ technology consists of a thin (2535 micron) polymeric film comprised of United States Pharmacopeia (USP)
`components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Derived from the edible film
`technology used for breath strips and initially developed for the instant delivery of savory flavors to food substrates, the
`VersaFilm™ technology is designed to provide a rapid response compared to existing conventional tablets. The VersaFilm™
`technology is intended for indications requiring rapid onset of action, such as migraine, opioid dependence, chronic pain,
`motion sickness, erectile dysfunction, and nausea.
`
`Our Multilayer Tablet platform technology allows for the development of oral controlledrelease products. It is designed to be
`versatile and to reduce manufacturing costs as compared to competing oral extendedrelease delivery technologies. The Oral
`Film technology allows for the instant delivery of pharmaceuticals to the oral cavity, while the Mucoadhesive Tablet allows for
`the controlled release of active substances to the oral mucosa.
`
`The Multilayer Tablet platform technology represents a new generation of controlled release layered tablets designed to
`modulate the release of active compounds. The technology is based on a multilayer tablet with an active core layer and
`erodible cover layers. The release of the active drug from the core matrix initially occurs in a firstorder fashion. As the cover
`layers start to erode, their permeability for the active ingredient through the cover layers increases. Thus, the Multilayer Tablet
`can produce quasilinear (zeroorder) kinetics for releasing a chemical compound over a desired period of time. The erosion rate
`of the cover layers can be customized according to the physicochemical properties of the active drug. In addition, our
`multilayer technology offers the opportunity to develop combination products in a regulatorycompliant format. Combination
`products are made up of two or more active ingredients that are combined into a single dosage form.
`
`The Mucoadhesive Tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site
`of application at a controlled rate. The Mucoadhesive Tablet is designed to provide the following advantages relative to
`competing technologies: (i) it avoids the first pass effect, whereby the liver metabolizes the active ingredient and greatly
`reduces the level of drug reaching the systemic circulation, (ii) it leads to a higher absorption rate in the oral cavity as compared
`to the conventional oral route, and (iii) it achieves a rapid onset of action for the drug. The Mucoadhesive Tablet technology is
`designed to be versatile in order to permit the site of application, residence time, and rate of release of the drug to be modulated
`to achieve the desired results.
`
`5
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`7/93
`
`Page 7 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`8/93
`
`Page 8 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`Product Portfolio
`
`Our product portfolio includes a blend of generic and branded products based on our proprietary delivery technology
`(“generic” products are essentially copies of products that have already received FDA approval). Of the thirteen projects
`currently in our product portfolio, two utilize our VersaTab™ technology, ten utilize our VersaFilm™ technology, and one
`utilizes our AdVersa™ technology.
`
`INT0001/2004: This is the most advanced generic product involving our multilayer tablet technology. Equivalency with the
`reference product Toprol XL® and its European equivalent BelocZOK® has been demonstrated invitro. The product has been
`tested in phase I studies. The project is currently on hold.
`
`INT0004/2006: We developed a new, higher strength of the antidepressant Bupropion HCl, the active ingredient in Wellbutrin
`XL®, and, in November 2011, the FDA approved the drug for patients with Major Depressive Disorder. In February 2012, we
`entered into an agreement with Edgemont Pharmaceuticals LLC (“Edgemont”) for commercialization of the product in the
`United States. Under the terms of the agreement, Edgemont obtained certain exclusive rights to market and sell the product in
`the U.S. In exchange we received a $1.0 million upfront payment, received launch related milestones totaling up to $4.0
`million, and are eligible for additional milestones of up to a further $23.5 million upon achieving certain sales and exclusivity
`targets. We also receive tiered doubledigit royalties on the net sales of the product. The agreement has no expiry date but may
`be terminated in the event of, without limitation (i) failure by either us or Edgemont to perform our respective obligations
`under the agreement; (ii) if either party files a petition for bankruptcy or insolvency or otherwise winds up, liquidates or
`dissolves its business, or (iii) otherwise by mutual consent of the parties. The agreement also contains customary
`confidentiality, indemnification and intellectual property protection provisions.
`
`The product was launched in the U.S. in October 2012 under the brand name Forfivo XL®. As of December 31, 2015 we have
`received an upfront payment of $1 million and a $1 million milestone payment related to the launch. The commercialization of
`Forfivo XL® triggered a launchrelated milestone payment of $3 million from IntelGenx’ licensing partner Edgemont due to
`Edgemont reaching in July 2015, $7 million of cumulative net trade sales of Forfivo XL® over the preceding 12 months. From
`that $3 million milestone payment, $1 million was received in Q3 2015. Of the remaining balance of $2 million, $1 million
`was received in Q4 2015 and $1 million was received in Q1 2016. We commenced receiving royalty payments in the first
`quarter of 2013. We recorded $433 thousand for the cost of royalty and license revenue in the twelvemonth period ended
`December 31, 2015 compared with $61 in the same period of 2014.
`
`The level of sales achieved for Forfivo XL® continues to improve significantly. According to Edgemont Pharmaceuticals, net
`sales of Forfivo XL® totaled $3 million in the fourth quarter ending December 31, 2015 compared to $2.4 million in the third
`quarter ending September 30, 2015, representing an increase of 24% according to the actual Edgemont Pharmaceutical sales
`report. For the past twelve months, net sales of Forfivo XL® totaled $9.3 million ($17.4 million gross), an increase of 102%
`compared to the comparative period of 2014 with net sales of $4.6 million ($7.7 million gross). Management expects the sales
`trend to continue in fiscal 2016.
`
`In August 2013 we announced receipt of a Paragraph IV Certification Letter from Wockhardt Bio AG, advising of the
`submission of an Abbreviated New Drug Application ("ANDA") to the FDA requesting authorization to manufacture and
`market generic versions of Forfivo XL® 450 mg capsules in the United States. In November 2014 we announced that the
`Paragraph IV litigation with Wockhardt had been settled and that, under the terms of the settlement, Wockhardt has been
`granted the right, with effect from January 15, 2018, to be the exclusive marketer and distributor of an authorized generic of
`Forfivo XL® in the U.S.
`
`In December 2014 we announced that Edgemont had exercised its right to extend the license for the exclusive marketing of
`Forfivo XL® 450 mg tablets. In exchange, we received milestone payments of $650 thousand in December 2014 and $600
`thousand in February 2015. All other financial obligations contained in the license agreement entered into by Edgemont and
`IntelGenx in February 2012, specifically launchrelated and sales milestones, together with the contractual royalty rates on net
`sales of the product, remain in effect.
`
`INT0007/2006: We are developing an oral film product based on our VersaFilm™ technology containing the active ingredient
`Tadalafil. The product is intended for the treatment of erectile dysfunction (ED). The results of a phase I pilot study that was
`conducted in the second quarter of 2015 confirmed that the product is bioequivalent with the brand product, Cialis®. We are
`currently manufacturing submission batches that are intended to support a 505(b)(2) NDA submission later this year.
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`9/93
`
`Page 9 of 93
`
`
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`30/03/2016
`INT0008/2007: In March 2013 we submitted a 505(b)(2) new drug application (“NDA”) to the FDA for our novel oral thin
`film formulation of Rizatriptan, the active drug in MaxaltMLT® orally disintegrating tablets. MaxaltMLT® is a leading
`branded antimigraine product marketed by Merck & Co. The thinfilm formulation of Rizatriptan was developed in
`accordance with a codevelopment and commercialization agreement with RedHill Biopharma Ltd. (“RedHill”). The product
`uses our proprietary immediate release VersaFilm™ oral drug delivery technology. In December 2011, we received approval by
`Health Canada to conduct a pivotal bioequivalence study to determine if our product is safe and bioequivalent with the FDA
`approved reference product, MaxaltMLT®. The trial was conducted in the second quarter of 2012 and was a randomized, two
`period, twoway crossover study in healthy male and female subjects. The study results indicate that the product is safe, and
`that the 90% confidence intervals of the three relevant parameters Cmax, AUC(0t) and AUC(0infinity) are well within the 80
`– 125 acceptance range for bioequivalency.
`
`6
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`10/93
`
`Page 10 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`In June 2013 the FDA assigned a Prescription Drug User Fee Act (“PDUFA”) action date of February 3, 2014 for the review of
`the NDA for marketing approval and in February 2014 we received a Complete Response Letter (“CRL”) from the FDA
`informing us that certain questions and deficiencies remain that preclude the approval of the application in its present form.
`The questions raised by the FDA in the CRL regarding the NDA for our antimigraine VersaFilm™ product primarily relate to
`third party Chemistry, Manufacturing and Controls (“CMC”) and to the packaging and labeling of the product. No questions or
`deficiencies were raised relating to the product's safety and the FDA's CRL does not require additional clinical studies.
`
`In March 2014 we submitted our response to the FDA's CRL and in April, 2014 the FDA requested additional CMC data. We
`also reported that the supplier of the active pharmaceutical ingredient (“API”) of the product has been issued with an “Import
`Alert” by the FDA. The Import Alert bans the import into the USA of all raw materials from the supplier’s manufacturing
`facility, which therefore prohibits the import of any products using these raw materials, and effectively prevents our
`VersaFilm™ product from being approved by the FDA at this time. We continue to work together with RedHill, our
`development partner, on a variety of options to ensure continued supply of the raw material. We plan to file a resubmission of
`the NDA in Q4, 2016 and expect to receive a new PDUFA date later in Q4, 2016. The PDUFA date for FDA approval is
`expected to be set by Q2 2017.
`
`In October 2014 we announced the submission of a Marketing Authorization Application (“MAA”) to the German Federal
`Institute for Drugs and Medical Devices (“BfArM”) seeking European marketing approval of our oral thin film formulation of
`Rizatriptan for acute migraines, under the brand name RIZAPORT®. The brand name RIZAPORT® was also conditionally
`approved by the FDA as part of the NDA review process in the U.S. The MAA was submitted under the European
`Decentralized Procedure (DCP) with Germany as the reference member state. The submission is supported by several studies,
`including a comparative bioavailability study which successfully established the bioequivalence between RIZAPORT® and
`the European reference drug. BfArM validated the MAA and initiated the formal review process of the application on
`November 25, 2014. BfArM granted national marketing approval on November 9, 2015 for RIZAPORT® under the DCP.
`
`INT0010/2006: We initially entered into an agreement with Cynapsus Therapeutics Inc. (formerly Cannasat Therapeutics Inc.,
`“Cynapsus”) for the development of a buccal mucoadhesive tablet product containing a cannabinoidbased drug for the
`treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy. A clinical biostudy undertaken in 2009
`on the mucoadhesive tablet developed by us and based on our proprietary AdVersa™ technology indicated improved
`bioavailability and reduced firstpass metabolization of the drug. In the fourth quarter of 2010, we acquired from Cynapsus full
`control of, and interest in, this project going forward. We also obtained worldwide rights to U.S. Patent 7,592,328 and all
`corresponding foreign patents and patent applications to exclusively develop and further provide intellectual property
`protection for this project.
`
`INT0027/2011: In accordance with a codevelopment and commercialization agreement with Par Pharmaceutical Companies,
`Inc. (“Par”), we developed an oral film product based on our proprietary VersaFilm™ technology. The product is a generic
`formulation of buprenorphine and naloxone Sublingual Film, indicated for maintenance treatment of opioid dependence. A
`bioequivalent film formulation was developed, scaledup, and pivotal batches manufactured and tested during a subsequent
`pivotal clinical study. An ANDA was filed with the FDA by Par in July 2013.
`
`In August 2013 we were notified that, in response to filing of the ANDA, we were named as a codefendant in a lawsuit
`pursuant to Paragraph IV litigation filed by Reckitt Benckiser Pharmaceuticals and Monosol RX in the U.S. District Court for
`the District of Delaware alleging infringement of U.S. Patent Nos. 8,475,832 and 8,017,150, each of which relate to
`Suboxone®. We believe the ANDA product does not infringe those or any other patents, and will vigorously defend ourselves
`in this matter. In accordance with the terms of the codevelopment and commercialization agreement, Par is financially
`responsible for the costs of this defense. Since Paragraph IV litigation is a regular part of the ANDA process, we do not expect
`any unanticipated impact on our already planned development schedule.
`
`INT0036/2013: Loxapine is for the treatment of anxiety and aggression in patients suffering from schizophrenia or bipolar 1
`disorder. Loxapine oral film will utilize the company's proprietary VersaFilm™ technology, allowing for an improved product
`to offer patients significant therapeutic benefits compared to existing medications. A fast acting loxapine oral film dosage form
`that can be used to effectively treat acute agitation associated with schizophrenia or bipolar 1 disorder in noninstitutionalized
`patients while reducing the risk of pulmonary problems is needed as it could substantially reduce the potential risks of violence
`and injury to patients and others by preventing or reducing the duration and severity of an episode of acute agitation. Our first
`clinical study on this product, completed in Q4 2014, suggested improved bioavailability compared to the currently approved
`tablet. A second pilot clinical study confirming the improved bioavailability compared to the current tablet was completed late
`2015. Further formulation optimization work is ongoing.
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`11/93
`
`Page 11 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`7
`
`http://www.sec.gov/Archives/edgar/data/1098880/000106299316008565/form10k.htm
`
`12/93
`
`Page 12 of 93
`
`
`
`30/03/2016
`
`IntelGenx Technologies Corp.: Form 10K Filed by newsfilecorp.com
`
`INT0037/2013: A product based on one of our proprietary technologies has been developed and we are currently preparing
`submission batches in support of a marketing application to the FDA. The product was being developed in accordance with
`another development and commercialization agreement with Par Pharmaceutical, Inc. On September 18, 2015, Par was acquired
`by Endo International plc. As a result of this acquisition, there was a conflict for Par to remain as the partner for these products.
`As such, the product was returned to the Company with full rights and no requirement for any compensation for work paid by
`Par. We continue to work closely with Par on the opioid dependence product and are pleased the relationship is on excellent
`terms. IntelGenx is now actively looking for a commercialization partner to conclude an agreement with to finalize the
`development of this product. Scaleup activities for the product commenced in 2015.
`
`INT0039/2013: A product based on